Shots:

• The collaboration is focused on development of Larazotide for Alcoholic Liver Diseases (ALD)- including severe alcoholic hepatitis
• Innovate will conduct an investor update on 17 Dec- 2018 for Larazotide- in celiac disease clinical program and NASH development strategy
• Larazotide (INN-202) is a synthetic eight amino acid peptide drug- completed P-II trial and expected to initiate P-III in H1’19 for celiac disease (previously planned to conduct in H2’18)

Ref: Innovate Pharmaceuticals | Image: Contract Pharma